Jordan Romero, 13, 'becomes youngest to scale Everest'
Jordan Romero was due to do some school work during his trip
A 13-year-old American boy has become the youngest person to reach the summit of Mount Everest, his family says.
Jordan Romero, from California, telephoned his mother from the peak of the world’s highest mountain, she said.
“Mom, I’m calling you from the top of the world,” Leigh Anne Drake quoted her son as saying.
He was climbing with his father and three Sherpa guides. The previous record was held by a Nepalese boy of 16.
The 13-year-old has now conquered the highest mountains on six of the world’s seven continents.
JORDAN’S SUMMITS
Continue reading the main story
- Africa – Kilimanjaro: 2006
- Europe – Elbrus: 2007
- South America – Aconcagua: 2007
- North America – Denali: 2008
- Oceania – Carstensz Pyramid: 2009
- Everest – Asia: 2010
He climbed Africa’s Mount Kilimanjaro aged 10. He just needs to scale the Vinson Massif in Antarctica.
He has also scaled Mount Kosciuszko in Australia.
The team set off from Nepal’s capital, Kathmandu, last month, heading for the base camp on the Chinese side of the mountain.
While Nepal insists that anyone planning to climb Mount Everest must be 16, China does not impose any age restrictions.
Some mountaineers have criticised the Romero family for letting him attempt the feat but his father said the ascent from the Chinese side is less dangerous, the AFP news agency reports.
Last month, his mother told the BBC he would do some school work during the trip.
Also on Saturday, Apa Sherpa, 50, climbed Everest for the 20th time, surpassing his own record.
Reference Link
http://news.bbc.co.uk/2/hi/world/asia_pacific/10141547.stm
Courtesy
The BBC
Sea sponge-derived drug treats several cancers
(Reuters) – An experimental new breast cancer drug made from sea sponges helped in a range of cancers, from breast cancer to sarcoma, researchers report.
Three studies show the drug, Eisai’s eribulin, was effective and tolerated in patients with breast cancer, colon cancer and urinary cancer, according to brief data released on Thursday by the American Society of Clinical Oncology. Sarcomas are cancers that grow from muscle or bone.
A fourth study of patients with advanced breast cancer will be detailed in a “late-breaker” session at ASCO’s annual meeting in June.
The drug is not yet approved, but Eisai has filed with relevant agencies in Japan, the United States and Europe.
The drug works on the same principle, but with a slightly different mechanism as older cancer drugs such as the taxanes and is infused intravenously.
Only a few details are available in the abstracts of the research published ahead of the meeting.
Researchers at Aichi Cancer Center in Nagoya, Japan and several other Japanese sites tested eribulin in 81 breast cancer patients whose cancer had come back despite several rounds of chemotherapy.
They said 21 percent of the patients had some response to the drug and side-effects were common — 95 percent had low blood counts. Nonetheless they said the drug was effective and tolerable.
Researchers at the European Organization for Research and Treatment of Cancer tested eribulin in several types of advanced soft tissue sarcoma and found varying responses but said it deserved further study.
Up to 45 percent of the patients with one type of sarcoma saw three months before their tumors began growing again — a significant result in advanced cancer.
And a team led by the California Cancer Consortium at the University of Southern California and elsewhere will report details of a mid-stage study of 40 patients with advanced urological cancer. They said 38 percent of the group had a response to eribulin.
An international team will report more details at the meeting itself in their trial of patients with breast cancer.
Reference Link
http://www.reuters.com/article/idUSTRE64K65520100521?feedType=nl&feedName=ushealth1100
Courtesy
Thomson Reuters
leave a comment